Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers

计划入组 131 人 · 首次发布于 2016 年 2 月 5 日

Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.

计划入组 105 人 · 首次发布于 2025 年 9 月 25 日

Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer

计划入组 14 人 · 首次发布于 2018 年 1 月 26 日

p300 histone acetyltranferase inhibitors (CBP mutant cancers/breast cancer/prostate cancer)

Mutant LRRK2 (ICBI)

Mutant APOBEC3G (NCI)

ASSO DE RECHERCHE CANCERS GYNECOLOGIQUES

France

Zymeworks

Canada

Rein Therapeutics

Enliven Therapeutics Advances ELVN-001 Toward Pivotal Phase 3 Trial in CML Amid Strong Financial Position

Zongertinib Shows Promising Efficacy and Tolerability in HER2-Mutant NSCLC

FDA Approves Boehringer Ingelheim's HERNEXEOS as First-in-Class HER2 TKI for Rare Lung Cancer Subset